FARMINGDALE, N.Y., Nov. 1, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical and medical applications, announced its recent attendance at the 26th Annual Clinical Symposium on Advances in Skin and Wound Care held in National Harbor, MD during September, 2011. Misonix exhibited and demonstrated its SonicOne® Ultrasonic Wound Cleansing and Debridement System to many of the more than 1,000 clinicians in attendance.
In addition, a clinical poster was presented that focused on the use of Contact Low Frequency Ultrasound as a Treatment Approach for Recalcitrant Wounds and Skin Conditions. John Bowman, PT, CWS, and Martin Smith, Technician, both from Retreat Doctors' Hospital, Richmond, VA, and Dana Wassum, DPT, from Virginia Commonwealth University, Richmond, VA, co-authored and presented their findings. The poster session focused on two separate clinical cases where wound closure had not been accomplished using standard wound care practices and compression. However, when contact, low frequency ultrasound, delivered by the SonicOne, was added to the treatment regimen, progression through the normal phases of wound healing began, with complete closure probable within a reasonable period of time. One conclusion of the authors was that the use of contact low frequency ultrasound as an adjunctive treatment modality appeared to be a very effective strategy to remove devitalized tissue in regard to efficacy, ease of use and outcome measures.
The SonicOne is an innovative wound care system designed to help address the challenges chronic wounds present to the patient, the healthcare professional and the healthcare system. The SonicOne System establishes a new standard in wound bed preparation, an essential first step in the wound healing process.
"Misonix is pleased to demonstrate its commitment to the rapidly expanding wound care market by supporting important educational programs like the Clinical Symposium on Advances in Skin and Wound Care," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We believe our wound care platform makes an important contribution to improving patient outcomes and we are pleased when data is presented that validates our investment in wound care research and development."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
|SOURCE Misonix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved